Patricia T Greipp

List of Publications by Year in Descending Order

153 papers	1,836 citations	22 h-index	39 g-index
169 ext. papers	2,463 ext. citations	4.2 avg, IF	4.41 L-index

#	Paper	IF	Citations
153	Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.. *Blood Cancer Journal*, **2022**, 12, 11	7	1
152	A simple additive staging system for newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 21	7	4
151	Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature.. *Annals of Diagnostic Pathology*, **2022**, 58, 151942	2.2	0
150	BAP1 Immunostain Status in Intraocular Biopsy Specimens for Uveal Melanoma Highly Correlates with Other Prognostic Markers.. *Ocular Oncology and Pathology*, **2022**, 8, 22-29	1.6	
149	Apparent coexistence of and fusions due to a nonproductive rearrangement in B-ALL.. *Leukemia and Lymphoma*, **2022**, 1-4	1.9	0
148	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. *Blood Cancer Journal*, **2022**, 12,	7	0
147	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. *Cancer Genetics*, **2021**, 260-261, 1-5	2.3	
146	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. *Blood Cancer Journal*, **2021**, 11, 184	7	0
145	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. *Blood*, **2021**, 138, 3771-3771	2.2	0
144	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). *Blood*, **2021**, 138, 2285-2285	2.2	
143	False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias. *Blood*, **2021**, 138, 4101-4101	2.2	
142	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. *Blood*, **2021**, 138, 3691-3691	2.2	0
141	Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. *British Journal of Haematology*, **2021**,	4.5	1
140	Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma. *American Journal of Clinical Pathology*, **2021**, 156, 129-138	1.9	2
139	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. *Blood Cancer Journal*, **2021**, 11, 43	7	3
138	Adult Philadelphia-like B-cell acute lymphoblastic leukemia: Characteristics, outcomes, and role of allogeneic hematopoietic cell transplantation in comparison to Philadelphia-positive and Philadelphia-negative acute lymphoblastic leukemia.. *Journal of Clinical Oncology*, **2021**, 39, 7022-7022	2.2	1
137	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. *American Journal of Hematology*, **2021**, 96, 945-953	7.1	2

136	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. *Blood Cancer Journal*, **2021**, 11, 122	7	0
135	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. *Genes Chromosomes and Cancer*, **2021**, 60, 678-686	5	1
134	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. *Human Pathology*, **2021**, 112, 20-34	3.7	2
133	Detection of a Cryptic EP300/ZNF384 Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia. *Laboratory Medicine*, **2021**, 52, 297-302	1.6	
132	Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia. *Genes Chromosomes and Cancer*, **2021**, 60, 108-111	5	1
131	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. *Transplantation and Cellular Therapy*, **2021**, 27, 165.e1-165.e11		4
130	Erythroblastic sarcoma transformation from a chronic myeloid neoplasm with FGFR1 rearrangement presenting as a pleural effusion: a case report. *Journal of Hematopathology*, **2021**, 14, 157-162	0.4	
129	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. *Blood Cancer Journal*, **2021**, 11, 18	7	3
128	Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. *Cancer Research*, **2021**, 81, 3333-3346	10.1	8
127	The Prognostic Role of Structural Variants Identified by NGS and FISH in Multiple Myeloma. *Clinical Cancer Research*, **2021**,	12.9	5
126	Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. *Annals of Diagnostic Pathology*, **2021**, 53, 151761	2.2	0
125	Disease outcomes and biomarkers of progression in smouldering Waldenstr□m macroglobulinaemia. *British Journal of Haematology*, **2021**, 195, 210-216	4.5	5
124	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. *Blood Cancer Journal*, **2021**, 11, 156	7	3
123	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, e710-e713	2	
122	Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. *Annals of Diagnostic Pathology*, **2020**, 46, 151533	2.2	3
121	Twin-to-twin transmission of transient abnormal myelopoiesis without constitutional trisomy 21: A case report. *Cancer Genetics*, **2020**, 244, 62-64	2.3	
120	Rare MDM2 amplification in a fat-predominant angiomyolipoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2020**, 477, 661-666	5.1	1
119	Characteristics of patients with myelodysplastic syndrome with balanced translocations. *British Journal of Haematology*, **2020**, 190, 244-248	4.5	1

118	Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. *Histopathology*, **2020**, 76, 1042-1054	7.3	7
117	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. *Annals of Hematology*, **2020**, 99, 513-518	3	1
116	Case Report with Review of the Literature: Uveal Melanoma in a Patient with Carney Complex - Another Rare Component of the Syndrome?. *Ocular Oncology and Pathology*, **2020**, 6, 311-317	1.6	2
115	Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. *Head and Neck Pathology*, **2020**, 14, 951-965	3.3	2
114	Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis. *Cancer Genetics*, **2020**, 243, 48-51	2.3	2
113	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. *Blood*, **2020**, 136, 9-10	2.2	
112	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. *Blood*, **2020**, 136, 26-27	2.2	
111	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. *Blood*, **2020**, 136, 44-44	2.2	
110	Heterogeneity of MYC Abnormalities in Multiple Myeloma. *Blood*, **2020**, 136, 2-3	2.2	
109	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 21-22	2.2	
108	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. *Blood Advances*, **2020**, 4, 2236-2244	7.8	7
107	Ibrutinib monotherapy outside of clinical trial setting in Waldenstrm macroglobulinaemia: practice patterns, toxicities and outcomes. *British Journal of Haematology*, **2020**, 188, 394-403	4.5	23
106	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. *American Journal of Hematology*, **2020**, 95, E68-E72	7.1	2
105	Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. *Cancer Genetics*, **2020**, 241, 67-71	2.3	1
104	Characterization of a cryptic fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative FISH studies. *Leukemia and Lymphoma*, **2020**, 61, 975-978	1.9	4
103	Impact of MYD88 mutation status on histological transformation of Waldenstrm Macroglobulinemia. *American Journal of Hematology*, **2020**, 95, 274-281	7.1	18
102	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. *Leukemia*, **2020**, 34, 1373-1382	10.7	22
101	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 6581-6588	12.9	9

100	Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature. *Annals of Diagnostic Pathology*, **2020**, 48, 151588	2.2	0
99	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. *Blood Advances*, **2020**, 4, 3509-3519	7.8	27
98	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer Journal*, **2020**, 10, 82	7	17
97	Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing. *Histopathology*, **2020**, 76, 481-485	7.3	3
96	Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia. *Genes Chromosomes and Cancer*, **2020**, 59, 422-427	5	4
95	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. *Blood Cancer Journal*, **2019**, 9, 73	7	19
94	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. *American Journal of Hematology*, **2019**, 94, E117-E120	7.1	6
93	Aurora kinase B-phosphorylated HP1 functions in chromosomal instability. *Cell Cycle*, **2019**, 18, 1407-1421	4.7	4
92	Characterization of a t(1;2)(p36;p21) involving the PRDM16 gene region by mate-pair sequencing (MPseq) in a patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes. *Journal of Hematopathology*, **2019**, 12, 85-90	0.4	
91	Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia. *Journal of Hematopathology*, **2019**, 12, 99-104	0.4	0
90	Elucidating a false-negative break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with and rearrangements. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	8
89	Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. *Human Pathology*, **2019**, 87, 65-74	3.7	22
88	Natural history of multiple myeloma with de novo del(17p). *Blood Cancer Journal*, **2019**, 9, 32	7	22
87	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. *Blood Cancer Journal*, **2019**, 9, 20	7	6
86	Detection of a cryptic gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	7
85	A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia. *Genes Chromosomes and Cancer*, **2019**, 58, 665-668	5	1
84	Hepatic Rearranged Epithelioid Hemangioendothelioma. *Case Reports in Gastrointestinal Medicine*, **2019**, 2019, 7530845	0.6	3
83	Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma. *Mayo Clinic Proceedings*, **2019**, 94, 1381-1384	6.4	5

82	Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. *Journal of Hematology and Oncology*, **2019**, 12, 73	22.4	35
81	Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 598-602	2	2
80	Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. *Cancer Genetics*, **2019**, 237, 51-54	2.3	3
79	Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. *Blood Cancer Journal*, **2019**, 9, 81	7	9
78	Atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma in patients aged ≤40 years: a study of 116 patients. *Histopathology*, **2019**, 75, 833-842	7.3	12
77	Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology and College of American Pathologists guidelines: The impact of combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) reflex testing in a large retrospective laboratory cohort. *Journal of Clinical Oncology*, **2019**, 37, 3141-3141	2.2	
76	Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype. *Blood*, **2019**, 134, 5210-5210	2.2	
75	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. *Blood*, **2019**, 134, 2588-2588	2.2	
74	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. *Blood*, **2019**, 134, 1800-1800	2.2	1
73	Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory. *Genes Chromosomes and Cancer*, **2019**, 58, 567-577	5	11
72	Impact of acquired del(17p) in multiple myeloma. *Blood Advances*, **2019**, 3, 1930-1938	7.8	20
71	Characterization of a cryptic rearrangement in a case of mantle cell lymphoma with negative FISH studies. *Blood Advances*, **2019**, 3, 1298-1302	7.8	11
70	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. *Blood Cancer Journal*, **2019**, 9, 103	7	18
69	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. *American Journal of Hematology*, **2019**, 94, 424-430	7.1	5
68	Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer. *Mayo Clinic Proceedings*, **2019**, 94, 27-36	6.4	4
67	Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. *Leukemia and Lymphoma*, **2019**, 60, 821-824	1.9	2
66	False-negative rates for fluorescence hybridization probes in B-cell neoplasms. *Haematologica*, **2019**, 104, e248-e251	6.6	16
65	Constitutional chromosome rearrangements that mimic the 2017 world health organization "acute myeloid leukemia with recurrent genetic abnormalities": A study of three cases and review of the literature. *Cancer Genetics*, **2019**, 230, 37-46	2.3	4

64	Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. *Human Pathology*, **2019**, 89, 109-114	3.7	6
63	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. *Leukemia and Lymphoma*, **2019**, 60, 990-999	1.9	5
62	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. *European Journal of Haematology*, **2019**, 102, 87-96	3.8	23
61	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815	10.7	18
60	De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. *Modern Pathology*, **2018**, 31, 705-717	9.8	17
59	Recurrent fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. *Blood* , **2018**, 131, 2262-2266	2.2	45
58	Polypoid fibroadipose tumors of the esophagus: 'giant fibrovascular polyp' or liposarcoma? A clinicopathological and molecular cytogenetic study of 13 cases. *Modern Pathology*, **2018**, 31, 337-342	9.8	18
57	Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. *Modern Pathology*, **2018**, 31, 141-149	9.8	33
56	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. *American Journal of Clinical Pathology*, **2018**, 150, 421-431	1.9	6
55	The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms: An ACLPS Critical Review. *American Journal of Clinical Pathology*, **2018**, 150, 375-384	1.9	9
54	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. *American Journal of Hematology*, **2018** , 93, E355-E357	7.1	2
53	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. *Blood*, **2018**, 132, 4460-4460	2.2	0
52	The impact of clonal size on the revised international prognostic scoring system (R-IPSS) in myelodysplastic syndromes (MDS) with a single cytogenetic abnormality.. *Journal of Clinical Oncology*, **2018**, 36, 7068-7068	2.2	
51	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome per 2017 WHO guideline compared to de novo MDS.. *Journal of Clinical Oncology*, **2018**, 36, e19026-e19026	2.2	
50	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. *Blood*, **2018**, 132, 5510-5510	2.2	
49	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449	2.2	
48	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 2884-2884	2.2	1
47	Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion. *Hepatology*, **2018**, 68, 1441-1447	11.2	26

46	Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma. *American Journal of Surgical Pathology*, **2018**, 42, 256-263	6.7	18
45	PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. *International Journal of Gynecological Pathology*, **2018**, 37, 537-546	3.2	5
44	A 10-Year Review of KMT2A Gene Fusion Partners Observed in Pediatric T-Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience. *American Journal of Clinical Pathology*, **2018**, 150, S132-S132	1.9	
43	Use of Mate-Pair Sequencing (MPseq) to Elucidate a Complex BCR-ABL1 Rearrangement Observed in a Newly Diagnosed Case of Chronic Myeloid Leukemia. *American Journal of Clinical Pathology*, **2018**, 150, S131-S132	1.9	
42	Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma. *Blood Cancer Journal* , **2018**, 8, 97	7	16
41	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. *Cancer Genetics*, **2018**, 228-229, 197-217	2.3	11
40	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, E398-E401	7.1	1
39	KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory. *Genes Chromosomes and Cancer*, **2018**, 57, 541-546	5	16
38	Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?. *American Journal of Clinical Pathology*, **2018**, 150, 168-176	1.9	4
37	12. Mate pair sequencing: Unveiling underappreciated complexity and providing clarity to the previously unanswered questions of cytogenetics. *Cancer Genetics*, **2018**, 224-225, 54-55	2.3	
36	Loss of p16 Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas. *Journal of Thoracic Oncology*, **2017**, 12, 860-871	8.9	14
35	Environmental exposures as a risk factor for fibrolamellar carcinoma. *Modern Pathology*, **2017**, 30, 892-898	9.8	4
34	Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 782-789	4.7	5
33	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. *Blood*, **2017**, 129, 3419-3427	2.2	244
32	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncology*, **2017**, 3, 1257-1265	13.4	82
31	Gastroblastoma harbors a recurrent somatic MALAT1-GLI1 fusion gene. *Modern Pathology*, **2017**, 30, 1443-1452	9.8	49
30	Outcome of patients younger than 50 years old diagnosed with myelodysplastic syndromes (MDS): Single institution experience.. *Journal of Clinical Oncology*, **2017**, 35, e18560-e18560	2.2	
29	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. *Blood*, **2016**, 128, 1234-45	2.2	77

28	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. *American Journal of Clinical Pathology*, **2016**, 145, 843-51	1.9	33
27	Clinical utility of myb rearrangement detection and p63/p40 immunophenotyping in the diagnosis of adenoid cystic carcinoma of minor salivary glands: a pilot study. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, **2016**, 121, 282-9	2	17
26	Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. *Blood*, **2016**, 128, 5541-5541	2.2	
25	Utilization of Mate-Pair Sequencing to Characterize Complex and Novel TCF3 Translocations. *Blood*, **2016**, 128, 4086-4086	2.2	
24	FGFR1 and FGFR2 in fibrolamellar carcinoma. *Histopathology*, **2016**, 68, 686-92	7.3	11
23	BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. *Cancer Genetics*, **2016**, 209, 223-8	2.3	14
22	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. *Cancer Letters*, **2016**, 380, 163-73	9.9	63
21	DNAJB1-PRKACA is specific for fibrolamellar carcinoma. *Modern Pathology*, **2015**, 28, 822-9	9.8	96
20	Brain metastasis of crystal-deficient, CD68-positive alveolar soft part sarcoma: ultrastructural features and differential diagnosis. *Ultrastructural Pathology*, **2015**, 39, 69-77	1.3	5
19	Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma. *Journal of Thoracic Oncology*, **2015**, 10, 1570-5	8.9	26
18	Ovarian Hemangiomas Do Not Harbor EWSR1 Rearrangements: Clinicopathologic Characterization of 10 Cases. *International Journal of Gynecological Pathology*, **2015**, 34, 437-44	3.2	6
17	Analysis of MDM2 Amplification in 43 Endometrial Stromal Tumors: A Potential Diagnostic Pitfall. *International Journal of Gynecological Pathology*, **2015**, 34, 576-83	3.2	27
16	Secondary Philadelphia chromosome and erythrophagocytosis in a relapsed acute myeloid leukemia after hematopoietic cell transplantation. *Cancer Genetics*, **2014**, 207, 268-71	2.3	4
15	Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. *Modern Pathology*, **2014**, 27, 113-27	9.8	58
14	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. *British Journal of Haematology*, **2013**, 163, 326-33	4.5	31
13	Primary cutaneous CD30-positive T-cell lymphoproliferative disorders with biallelic rearrangements of DUSP22. *Journal of Investigative Dermatology*, **2013**, 133, 1680-2	4.3	14
12	Very High Risk CLL Characterized by a Double Hit Clone with Both 11q22 and 17p13 Deletion.. *Blood*, **2012**, 120, 2486-2486	2.2	
11	FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,. *Blood*, **2011**, 118, 3538-3538	2.2	

10	Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. *Mayo Clinic Proceedings*, **2010**, 85, 905-12	6.4	96
9	FISH Redoux A Novel Way to Emulate CLL Leukemic Cells From Buffy Coat Samples. *Blood*, **2010**, 116, 3606-3606	2.2	
8	Isolated Trisomy 8 in the Myelodysplastic Syndromes.. *Blood*, **2009**, 114, 2785-2785	2.2	
7	Whole Arm Duplication of 1q in Myeloid Neoplasm, with Emphasis On Derivative (1;7)(q10;p10).. *Blood*, **2009**, 114, 4238-4238	2.2	
6	Anti-CD20 monoclonal antibody therapy in multiple myeloma. *British Journal of Haematology*, **2008**, 141, 135-48	4.5	83
5	In-111DAC Is a Novel Technique To Image Multiple Myeloma.. *Blood*, **2006**, 108, 3488-3488	2.2	1
4	Myeloma with t(11;14) and CD20+ Plasma Cells: Response to Rituximab.. *Blood*, **2005**, 106, 5178-5178	2.2	
3	Prevalence, breakpoint distribution, and clinical correlates of t(5;12). *Cancer Genetics and Cytogenetics*, **2004**, 153, 170-2		30
2	Plasma Cell Folate Receptor Overexpression Differentiates Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma.. *Blood*, **2004**, 104, 3649-3649	2.2	0
1	Spurious CD34 expression in B-cell lymphoma due to nonspecific binding to PerCP-Cy5 .5 fluorochrome conjugates: A rare phenomenon and a diagnostic pitfall. *Cytometry Part B - Clinical Cytometry*,	3.4	2